Business
U.K. University Creates Postgraduate Course on Clinical Psychedelics
The University of Exeter takes a crucial step in securing psychedelic therapy’s reputation.
The University of Exeter, a university in the United Kingdom, is debuting one of the first postgraduate qualifications on psychedelics in the world, the Guardian reports. The program, called Psychedelics: Mind, Medicine, and Culture, aims to capitalize on Exeter’s lauded psychedelics research center by sharing their expertise through training with therapists, mental health advocates, healthcare workers, and anyone else in the space of psychedelics. The University of Exeter recently unveiled the plans at Europe’s largest psychedelics conference Breaking Convention.
The “psychedelic renaissance” is going global. Australia established itself as the first country to allow psychiatrists to prescribe psychedelics for treatment-resistant depression. And now, we can appreciate further efforts such as The University of Exeter’s training across the pond. In the United States, this is demonstrated in ketamine-assisted therapy for treatment-resistant depression, to the legalization efforts of psilocybin therapy in states like Oregon and Colorado, to the soon-to-be-secured legal status of MDMA to treat PTSD. Of course, remember that indigenous cultures, as with their relationship with peyote, have consistently recognized the spiritual benefits of psychedelic therapy, so the word “renaissance” is always used with a caveat.
With that in mind, granted that as a result of the pandemic, mental health is on everyone’s minds, whether they’re struggling and searching for the proper treatment or looking to help others through psychedelics (or both). Therefore, any help in normalizing the psychedelic medicine community is welcome. This is especially true if the information is rooted in science and directed at communities that need it most, such as those treating mental health patients, such as Psychedelics: Mind, Medicine, and Culture.
Reflecting the growing interest and new (by our standards) acceptance of psychedelic medicine, the Guardian reports that the psychedelic healthcare market will be worth $8.3 billion by 2028. Psychedelics: Mind, Medicine, and Culture aim to educate healthcare workers on how to safely work with psilocybin, LSD, MDMA, and other psychoactive drugs in therapeutic work, to help ensure that money creates the best outcome for patients.
In addition to successfully spreading science-approved info on psychedelics by creating a certificate on the topic with the backing of the respected Exeter University, this program aims to garner trust from outside parties regarding the safety and efficacy of psychedelic-assisted therapies. Psychedelics: Mind, Medicine, and Culture also aims to pave the way for other programs, creating a blueprint that could help introduce new therapies that will become available over the next five years as treatments finish their final stages of clinical trials.
Celia Morgan, a professor of psychopharmacology at the University of Exeter and a co-lead of the program, said: “As the world wakes up to the potential for psychedelics to be an important part of the toolkit to treat some of our most damaging mental health conditions, it’s vital that we’re training the workforce to meet the demand. The global body of high-quality evidence is now irrefutable – psychedelics can work where other treatments have failed.”
Morgan made sure to note that the most significant challenges to accessing psychedelic therapeutic mental health care were legal rather than about any medical risk. She continued: “This shows how far we have come from the fear and stigma that dogged this field for years, a change which we also see reflected in leading universities around the world conducting gold-standard clinical trials…we remain optimistic that this may change in the UK with the increasing weight of evidence, as it is starting to in countries like the US and Australia.”
University of Exeter’s postgraduate program includes existing psychedelic therapies, psychiatry and neuroscience, and philosophy, in addition to addressing the importance of decolonizing psychedelic research.
Source: https://hightimes.com/news/u-k-university-creates-postgraduate-course-on-clinical-psychedelics/
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Business
Marijuana companies suing US attorney general in federal prohibition challenge
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Business
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business1 year ago
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year ago
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year ago
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year ago
Washington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year ago
Marijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year ago
Legal Marijuana Handed A Nothing Burger From NY State
-
Business1 year ago
Can Cannabis Help Seasonal Depression
-
Blogs1 year ago
Cannabis Art Is Flourishing On Etsy